NasdaqGS:PRAXBiotechs
Praxis Precision Medicines (PRAX) Valuation After Vormatrigine POWER1 Miss And POWER2 Trial Pause
Praxis Precision Medicines (PRAX) has moved into focus after reporting Phase 2/3 POWER1 data for vormatrigine in focal onset seizures, missing the primary endpoint while hitting a key secondary measure and pausing the follow on POWER2 trial.
See our latest analysis for Praxis Precision Medicines.
The vormatrigine setback has triggered a sharp pullback, with a 1 day share price return down 4.06% and a 7 day share price return down 27.42%. However, the 1 year total shareholder return is still...